Allergan ROE 2006-2018 | AGN

Current and historical return on equity (ROE) values for Allergan (AGN) over the last 10 years.
Allergan Annual ROE - Return on Equity
2017 -5.39
2016 -1.31
2015 -4.11
2014 -8.77
2013 -4.90
2012 2.55
2011 7.27
2010 5.58
2009 7.34
2008 11.31
2007 7.62
2006 -26.48
2005 6.60
Allergan Quarterly ROE - Return on Equity
Q2 2018 -0.66
Q1 2018 -0.39
Q4 2017 5.09
Q3 2017 -5.96
Q2 2017 -1.02
Q1 2017 -3.65
Q4 2016 -0.06
Q3 2016 -0.45
Q2 2016 -0.59
Q1 2016 -0.13
Q4 2015 -1.13
Q3 2015 -1.21
Q2 2015 -0.66
Q1 2015 -1.18
Q4 2014 -2.59
Q3 2014 -3.99
Q2 2014 0.50
Q1 2014 1.00
Q4 2013 -1.56
Q3 2013 1.75
Q2 2013 -15.95
Q1 2013 -2.86
Q4 2012 0.75
Q3 2012 2.08
Q2 2012 -1.75
Q1 2012 1.50
Q4 2011 2.64
Q3 2011 1.94
Q2 2011 1.51
Q1 2011 1.33
Q4 2010 0.52
Q3 2010 0.80
Q2 2010 2.25
Q1 2010 2.26
Q4 2009 1.88
Q3 2009 2.73
Q2 2009 2.37
Q1 2009 2.27
Q4 2008 2.68
Q3 2008 3.47
Q2 2008 3.06
Q1 2008 2.66
Q4 2007 2.08
Q3 2007 1.92
Q2 2007 2.06
Q1 2007 1.85
Q4 2006 -29.10
Q3 2006 1.59
Q2 2006 -0.73
Q1 2006 1.18
Q4 2005 0.97
Q3 2005 1.87
Q2 2005 1.88
Q1 2005 1.74
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $62.458B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $22.859B 6.39
Mylan (MYL) United Kingdom $19.184B 8.16
Bausch Health Cos (BHC) Canada $7.619B 5.69
Dr Reddy's Laboratories (RDY) India $5.346B 23.88
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.588B 4.40
Supernus Pharmaceuticals (SUPN) United States $2.410B 25.78
Akorn (AKRX) United States $2.332B 11.55
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.801B 115.47
CymaBay Therapeutics (CBAY) United States $0.714B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.628B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Voyager Therapeutics (VYGR) United States $0.589B 0.00
Homology Medicines (FIXX) United States $0.582B 0.00
Corium (CORI) United States $0.314B 0.00
Teligent (TLGT) United States $0.220B 0.00
Sol-Gel Technologies (SLGL) Israel $0.124B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.115B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.073B 0.00
Versartis (VSAR) United States $0.063B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.043B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.023B 0.00
Acasti Pharma (ACST) Canada $0.019B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00